Sandoz Navigates Legal Challenges and Strategic Growth in Switzerland
Swiss generic drugs giant Sandoz has faced a turbulent first half of the year, with profits plummeting by 70% due to substantial legal costs. The company, which became independent from Novartis in October 2023, has been grappling with the financial impact of long-running litigation in the United States. Despite these challenges, Sandoz has taken decisive steps to resolve its legal woes and position itself for future growth.
In a significant development, Sandoz has agreed to pay $450 million as part of a settlement with 43 US states and territories, along with a group of indirect resellers, in the generic drug pricing litigation. This settlement marks a crucial step in clearing the legal overhang, with only claims from individual plaintiffs who opted out of earlier class action settlements remaining. The company’s proactive approach to resolving these disputes underscores its commitment to moving forward and focusing on its core business.
Amid these legal challenges, Sandoz has also celebrated a major milestone: its inclusion in the Swiss Market Index (SMI). Richard Saynor, CEO of Sandoz, highlighted the significance of this achievement, stating, “Our inclusion in the SMI is an important milestone, illustrating our evolution as an independent company and the growing confidence investors have in our strategy, execution and long-term growth prospects.” This recognition reflects the market’s optimism about Sandoz’s future, particularly as it prepares to capitalize on an unprecedented wave of loss of exclusivity opportunities, which the company calls its “golden decade.”
To support its strategic ambitions, Sandoz has announced key leadership changes. Keren, who previously served as Global Head of M&A at Novartis, has joined Sandoz to lead global business development, bringing extensive experience in major acquisitions and portfolio transformation. Additionally, Simon Goeller, currently Global Head of Transformation & Growth, has been appointed Country President for Germany, one of Sandoz’s most important markets, effective August 1, 2026. These appointments reinforce Sandoz’s commitment to operational excellence, strategic growth, and expanding its leadership across key international markets as it enters its next phase of development.
Shimanta Das 
